Treatment of chronic myelogenous leukemia (CML) with interferon-a frequently results in normalization of peripheral blood counts and, in up to 20% of patients, reestablishment of normal hematopoiesis. We hypothesize that interferon-ar may restore normal adhesive interactions between CML progenitors and the bone marrow microenvironment and restore normal growth regulatory effects resulting from these progenitor-stroma interactions. We demonstrate that treatment with interferon-a induces a significant, dose-dependent increase in the adhesion of primitive long-term culture initiating cells and committed colony-forming cells (CFC) from CML bone marrow to normal stroma. Adhesion of CFC seen after interferon-a treatment could be inhibited by blocking antibodies directed at the a4, a5, and ,B1 integrins and vascular cell adhesion molecule, but not CD44 or intracellular adhesion molecule, suggesting that interferon-a induces normalization of progenitor-stroma interactions in CML. Because FACS® analysis showed that the level of a4, a5, and fl1 integrin expression after interferon-a treatment is unchanged, this suggests that interferon-a may restore normal f81 integrin function. Normalization of interactions between CML progenitors and the bone marrow microenvironment may then result in the restoration of normal regulation of CML progenitor proliferation, and explain, at least in part, the therapeutic efficacy of interferonat in CML. (J. Clin. Invest. 1994. 94:384-391.)
Introduction
Chronic myelogenous leukemia (CML), 1 a malignancy arising from the hematopoietic stem cell, is characterized by a vast expansion of hematopoietic cells belonging to the malignant clone resulting from unregulated proliferation of hematopoietic progenitors ( 1). In addition, greatly increased numbers of circulating progenitors are seen as a result of their premature release into the circulation (2) . Malignant CML cells are characterized cytogenetically by a translocation between chromosomes 9 and 22 (t9: 22) , the Philadelphia chromosome (3) , and at the molecular level by the bcr/abl fusion oncogene (4) .
Unregulated proliferation and abnormal circulation of CML malignant progenitors can, at least in part, be explained by abnormal adhesive interactions between the bone marrow microenvironment and CML progenitors. Close contact between normal progenitors and stroma is thought to be important not only for localization of hematopoiesis in the bone marrow but also for regulation of progenitor cell growth. Normal primitive hematopoietic progenitors present in close contact with bone marrow stroma are usually quiescent (5) . This may be the result of increased availability of growth inhibitory cytokines such as transforming growth factor-3 (TGF-f3) and macrophage inflammatory protein-la (MIP-la) in proximity with the bone marrow stroma (6) (7) (8) (9) . Recent studies from our laboratory suggest also that direct contact per se between normal progenitors and stroma may inhibit progenitor proliferation (10, 11) . Normal progenitors adhere to stroma through a variety of cell surface adhesion receptors including the a4f31 integrin receptors which can bind to VCAM and the CS-I region in the COOHterminal heparin binding domain of fibronectin and a5,(1 integrin receptors which recognize the RGD containing cell binding domain of fibronectin (12) (13) (14) (15) (16) . Unlike normal progenitors, CML progenitors fail to adhere to normal stromal layers (17, 18) and to fibronectin or its proteolytic fragments (18) . However, a4,61 and a5,681 integrin receptors are present at normal levels on CML progenitors, which suggests that the function of these receptors may be impaired in CML ( 18) . Since a4f31 and a5,61 receptors may transmit proliferation inhibitory signals from the microenvironment to normal hematopoietic progenitors, decreased adhesion of CML progenitors to the microenvironment through these receptors may underly the observation that CML progenitors in the stromal adherent layer of long-term bone marrow cultures (LTBMC) are continuously proliferating.
Interferon-a has been used successfully in the treatment of CML. Treatment with interferon-a induces hematologic remissions in up to 75% of patients treated. Moreover, interferon-a treatment can result in a gradual, selective suppression of the malignant clone with restoration of normal nonclonal hematopoiesis (19) . The mechanism s) by which interferon-a restores normal hematopoiesis in CML is not clear. It has been demonstrated that interferon pretreatment of normal bone marrow In this regard, interferon-a can restore the deficient expression of LFA-3 on CML progenitor cells suggesting that it may similarly enhance expression of other critical adhesion receptors that may be deficient on CML progenitors (21) .
To further elucidate the mechanisms whereby interferon-a restores normal hematopoiesis in CML, we studied the effect of interferon-a treatment of CML progenitors on their adhesion to normal BM stroma. Treatment of CML progenitors with interferon-a resulted in enhanced progenitor adhesion to stroma in a dose-dependent fashion. We demonstrate that adhesion of interferon-a-treated cells to normal stroma involves the a4/31 and a5p3I integrin receptors and that this is the result of modulation of receptor function rather than an increase in their quantitative expression.
Methods
Bone marrow samples 14 patients with CML and 9 normal healthy volunteers were evaluated after informed consent was obtained using guidelines approved by the Committee on the Use of Human Subjects at the University of Minne 
Cell adhesion assays
Normal DR-and DR+ and CML DR+ progenitor cells were incubated in bone marrow stroma conditioned medium (CM) containing interferon-a2b (Schering Corp., Kenilworth, NJ) at 37°C in a humidified atmosphere with 5% CO2. The interferon concentrations used ranged from 100 to 10,000 U/ml. Cells were exposed to interferon-a for time periods ranging from 20 in the CML DR+ population adhere significantly less to normal stroma compared with normal CFC. Interferon-a treatment resulted in a significant increase in the adhesion of CML LTC-IC to normal bone marrow stroma (P < 0.05, n = 5) (Fig. 1  a) . Similarly, significantly more committed CML progenitors [BFU-E (P < 0.001, n = 13), CFU-GM (P = 0.001, n = 13) and CFU-MIX (P < 0.001, n = 10)] (Fig. 1 a) adhered to normal stroma after interferon-a treatment. In contrast, adhesion of normal bone marrow derived LTC-IC, BFU-E, CFU-GM and CFU-MIX was not significantly increased after interferona treatment (Fig. 1 b) . Although growth of CML progenitors could be suppressed following pretreatment with interferon-a [progenitor growth after interferon-a treatment compared with growth of controls not exposed to interferon: BFU-E, 77.9+7.3% (n = 13); CFU-GM, 94.8±7.3% (n = 13); CFU-MIX, 92.1±4.3% (n = 10) and LTC-IC, 89.2+8.5% (n = 5)], this did not affect the results of adhesion assays, since the percent adherent progenitor cells was calculated by dividing the number of colonies generated in cultures initiated with panned cells by the number of colonies in cultures initiated with plated cells under identical conditions. The increased adhesion of interferon-a treated CML progenitors to bone marrow stroma was dose-dependent (Fig. 2) . Adhesion to stroma of both CML LTC-IC and CFC did not differ significantly from that of normal progenitors once CML progenitors were pretreated with 1 X 103 to 1 X 104 U/ml interferon-a. At least 12 h of incubation with interferon-a was required before significantly increased adhesion of CML progenitors to bone marrow stroma was observed (Fig. 3) although a further increase in adhesion could be seen after 48 h of incubation.
Receptors involved in the adhesion of interferon-a-treated CML progenitors to stroma. The role of a4/31, a5/lI and VCAM, known to be involved in the adhesion of normal committed progenitors to BM stroma, in the adhesion of interferona-treated CML progenitors was evaluated by studying the ability of antibodies directed against these receptors to block adhesion. CML DR+ cells, incubated with or without interferon-a (10,000 U/ml) for 48 h, were washed and allowed to adhere to normal BM stromal layers for 2 h in the presence of antibodies against a4, aS, /B1, CD44, VCAM, and ICAM-1.
The low level adhesion to stroma of CML CFC, in the absence of interferon-a, was not significantly inhibited by antibodies against a4, aS, /31, and VCAM [BFU-E: control adhesion 25 Fig. 4 a, adhesion of CML BFU-E, treated with interferon-a, to normal BM stroma was significantly inhibited by antibodies against the a-4 (P < 0.01), a-5 (P = 0.005), and 6-1 (P < 0.001) integrin receptors as well as to VCAM (P < 0.05, n = 4). Antibodies against the CD44 receptor (5OB4 and Hermes-3) and ICAM-1 did not have a significant effect on adhesion. Similar results were obtained for CML CFU-GM (Fig. 4 b) .
The effect of these antibodies on the adhesion of interferon-a- -~x labeled with antibodies against integrin receptors and CD34 and analyzed using FACS@. Cells with low vertical and horizontal light scatter properties and expressing high levels of CD34 antigen were evaluated for expression of integrin receptors by frequency histogram. Fig. 5 shows representative histograms obtained from one such patient. As we have previously demonstrated, CML CD34+ cells express similar levels of the a4, a5, and /I integrins as normal CD34+ cells (18) . No change in receptor expression was observed after interferon-a treatment, suggesting that interferon-a may restore /3-1 integrin receptor function rather than up-regulating the level of receptor expression.
Discussion
Interferon-a treatment of CML can result in the selective suppression of malignant hematopoietic progenitors and resumpi JaSUIT tion of normal hematopoiesis (19) . The mechanism(s) whereby interferon achieves this effect are not clear. It has been demonstrated that CML progenitors, which fail to adhere to normal bone marrow stroma, can adhere to normal stromal layers after treatment of stroma with interferon-a (20) . We demonstrate here that interferon-a can increase adhesion of CML progenitors to stroma through a direct effect on the progenitors involving upregulation of a4/31 and a5lI integrin receptor function. Restoration of normal adhesive interactions between CML progenitors and stroma may then result in restoration of normal growth regulatory mechanisms, which in normal individuals are thought to be dependent on close progenitor-stroma interactions (5, 6, 10, 11) .
Integrins are heterodimeric receptors consisting of a and chains which possess a large extracellular domain, a transmembrane domain and a short intracellular domain (26) . The role of integrin receptors in hematopoiesis has recently gained interest. a4/31 and a5p 1 integrin receptors are present on normal progenitors and are involved in the adhesion of these progenitors to stroma (12) (13) (14) (15) (16) . We have previously demonstrated that CML progenitors express similar levels of cell surface a4fi1 and a5lI1 integrin receptors as normal progenitors (18) . However, CML progenitors are deficient in their ability to adhere to stroma or to purified fibronectin and fibronectin proteolytic fragments (18, 19) suggesting that these receptors are present in a functionally inactive state. A variety of studies have demonstrated that the mere presence of integrin receptors does not necessarily indicate that the receptor has functional significance (26) . Integrins can be present in a nonfunctional low affinity state that can be switched to a high affinity state after stimulation of the cell with cytokines (9), through other cell surface receptors (27) or through its own ligands (28 (33) . Recent studies have demonstrated that interferon-a may prevent transcription of the bcr/abl mRNA, and hence expression of the p21Olcr/abI tyrosine kinase (34) . Removal of the p210bCr'abl neoprotein and its possible effect on integrin affinity may then explain the restored adhesion of progenitors following interferon-a treatment. The time required for interferon-a to cause enhanced adhesion of CML progenitors to stroma is consistent with an effect mediated by alteration in mRNA and/or protein synthesis. It is also possible that interferon-a may act on CML progenitors to upregulate certain other adhesion receptors, which we have not evaluated, such as members of the selectin family (35) . Stimulation of CML progenitors through these receptors could subsequently result in enhanced affinity of /31 integrin receptors (27) .
Adhesion through integrins serves not only to localize cells within specific microenvironments, but may also have profound effects on cell growth and differentiation. Engagement of integrins results in cytoskeletal rearrangement (36) , tyrosine phosphorylation of certain cytoplasmic proteins (37), and, depending on the cell type, in either increased proliferation (38) , with associated increased expression of AP-1 (fos/jun) (39), or reduced proliferation and induction of differentiation (40) . The importance of signal transduction through integrin receptors on hematopoietic progenitors has been less well studied. Normal primitive progenitors adherent to bone marrow stroma are usually quiescent (5) . Recent studies from our laboratory suggest that inhibition of proliferation of normal progenitors in contact with stroma may result from the adhesive interaction itself with stroma and extracellular matrix, specifically fibronectin (10, 11) . It is therefore possible that impaired integrin receptor function on CML progenitors (18) may lead to reduced growth inhibition, thereby providing an explanation for the observation that CML progenitors present within the adherent layer of stromal cultures are continuously proliferating (1) . Modulation of a4/31 and aS/p3 function on CML progenitors by interferon-a may then restore normal growth inhibitory signal transduction pathways, leading to normal regulation of proliferation. In addition, inhibition of proliferation of normal progenitors as a result of adhesion to stroma may result from colocalization of progenitors with negative growth regulatory factors, such as transforming growth factor-/ or macrophage inflammatory proteinla, which are bound and concentrated by the extracellular matrix (6) (7) (8) (9) . Such interactions would be expected to be impaired in CML because of impaired adhesion to stroma. Restored adhesion induced by interferon-a may then allow normal regulation of CML progenitors by these negative growth regulatory factors.
In conclusion, the present study demonstrates that interferon-a restores normal adhesive interactions between CML progenitors and the bone marrow microenvironment through upregulation of /31 integrin function. Further studies will be required to characterize the functional defect of abnormal /1 integrin receptors in CML and the mechanisms by which interferon-a modulates receptor function. This knowledge may help in the development of improved treatment strategies for this disease.
